Acute Myeloid Leukaemia (AML) is a complex and aggressive blood cancer with low survival rates, driven by mutations in transcription factors such as RUNX1 and chromatin modifiers. This PhD project at the University of Nottingham's School of Medicine focuses on a newly discovered RUNX1 mutation that produces a novel oncoprotein with a 116-amino acid extension. This mutation is largely uncharacterised and is believed to interact with chromatin modifiers, contributing to the development of leukaemia.

The research will combine advanced structural and biochemical analysis of the oncoprotein and its interaction partners with next-generation sequencing and computational biology approaches. You will use induced pluripotent stem cells derived from a patient carrying this mutation to investigate how disruption of gene regulation by specific chromatin modifiers affects blood cell development. The findings will help inform new strategies for treating AML patients with this previously unknown mutation type.

The project is supervised by Professor Alex Thompson (lead supervisor), Sophie Kellaway, and John Schwabe, offering expertise in molecular biology, cancer biology, and structural biology. The position is fully funded by the Medical Research Council for four years, covering a stipend, tuition fees (home and international rates), laptop allowance, research training and support grant (£5,000 per annum), and travel allowance (£300 per annum).

Applicants should have a strong academic background in biological sciences, biochemistry, molecular biology, or related fields, with a first or upper second class undergraduate degree (or equivalent). Experience in laboratory research, bioinformatics, or computational biology is desirable. International applicants are welcome, but recruitment is capped at 30% of the cohort. English language proficiency may be required for non-native speakers.

To apply, visit the MRC AIM website and complete the application form, ensuring all supporting documents are provided. For project enquiries, contact Professor Alex Thompson. The application deadline is 12:00 pm GMT on January 9, 2026.

References supporting the research context include key studies on genomic classification and prognosis in AML, molecular basis of RUNX1 mutations, and therapeutic targeting in hematologic malignancies.